New Horizons in Unresectable Stage III NSCLC: A Case-based Exploration of Evolving Data and the Emergence of Immunotherapy

09/09/22 • 60 min

Join our Expert Faculty, Drs. Joel W. Neal, MD, PhD and Victoria Sherry, DNP, CRNP, AOCNP as they discuss treatment principles across the continuum of care in unresectable, stage III NSCLC. During their presentations and discussion, they will examine the established treatment landscape for unresectable, stage III NSCLC as well as the emerging role of immunotherapy, and practical clinical considerations for anticipating, mitigating, and managing immune-related adverse events.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from AstraZeneca.

Previous Episode

Breaking the Cycle in Cardiorenal Anemia Syndrome: The Practice-changing Role of IV Iron at the CKD–Heart Failure Interface

All clinicians managing patients with non-dialysis-dependent chronic kidney disease or heart failure must be aware of the deleterious impacts of concomitant anemia and the established, emerging, and practice-changing role of intravenous (IV) iron therapies. The vicious cycle of cardiorenal anemia syndrome (CRAS)—the pathologic triad wherein the three conditions are each capable of causing and/or being caused by the other—can be effectively mitigated and managed with IV iron. Unfortunately, clinician hesitancy in prescribing IV iron, largely due to adverse effects associated with earlier formulations, must be overcome before the full benefit of IV iron in CRAS can be realized. Join Drs. Matthew Weir and Javed Butler as they address CRAS pathophysiology, examine applicable expert consensus guidelines, and review current evidence for treatment. Practical, case-based elements will be offered that provide learners with real-world examples of IV iron safety, efficacy, and the need for multidisciplinary (nephrologist-cardiologist-PCP) care.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from American Regent.

Next Episode

undefined - Overcoming Pediatric Iron Deficiency Anemia with IV Iron: Interprofessional Approaches to Integrating New Data, Using Novel Agents, and Optimizing Care

Overcoming Pediatric Iron Deficiency Anemia with IV Iron: Interprofessional Approaches to Integrating New Data, Using Novel Agents, and Optimizing Care

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/iv-gr-podcast#group-tabs-node-course-default1Learning Objectives

Review the clinical gravity and foundational pathophysiology of iron deficiency anemia (IDA) in pediatric patients, with an emphasis on patient impact and the need for treatment.
Evaluate the evolving clinical trial evidentiary base for intravenous (IV) iron as IDA management in pediatric patients, including a summary of recent FDA approvals and updated label indications for IV iron therapies.
Discuss practical aspects of IV iron usage in the pediatric setting, including appropriate dosing, safety considerations, and clinician adherence to evidence-based IDA treatment standards.
Use a real-world, case-based format to design evidence-supported strategies for recognizing, diagnosing, treating, and evaluating IDA in pediatric patients, focusing on the interpolation of IV iron into the management paradigm.

Presented By:
Jacquelyn M. Powers, MD, MS
Assistant Professor of Pediatrics
Associate Chief, Pediatric Hematology
Baylor College of Medicine
Texas Children's Cancer and Hematology Centers
Houston, TX